Evidence map›Paper›PMID 23022997›Full record

ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2013

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

I Vaz-Luis, E P Winer, N U Lin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. HER2-Positive Breast Cancer Treatment and Resistance.Advances in experimental medicine and biology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

I Vaz-LuisDepartment of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA; Clinical and Translational Oncology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal.
E P WinerDepartment of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
N U LinDepartment of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA. Electronic address: nancy_lin@dfci.harvard.edu.

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Intramural NIH HHSNCRR NIH HHS UL1 RR025758
6 · The paper itself

Abstract

backgroundHuman epidermal growth factor receptor-2 (HER2) overexpression occurs in ∼20% of breast cancers and has historically been associated with decreased survival. Despite substantial improvements in clinical outcomes, particularly with the emergence of HER2-targeted therapy, a substantial minority of patients still relapses, and progression is inevitable in metastatic disease. Accumulating data indicate that HER2-positive disease is itself a heterogeneous entity. METHODS AND

resultsIn this article, we qualitatively review the data supporting the classification of HER2-positive disease as at least two separate entities, distinguished by estrogen receptor (ER) status. We summarize differences in clinical outcomes, including response to neoadjuvant therapy, timing and patterns of dissemination, efficacy of therapy in the metastatic setting and survival outcomes.

conclusionsThe collective data are sufficiently strong at this point to propose that ER status defines two distinct subtypes within HER2-positive breast cancer, and we highlight the implications of this knowledge in future research, including understanding of the basic biology of HER2-positive breast cancer and the design of future clinical trials.

Indexed as

Antibodies, Monoclonal, HumanizedBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibNeoadjuvant TherapyNeoplasm Recurrence, LocalQuinazolinesReceptors, AndrogenReceptors, EstrogenTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibpertuzumabQuinazolinesReceptors, AndrogenReceptors, Estrogen

Identifiers

PMID23022997
PMCPMC3551479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.